One manager, Steve Cohen's Point72, has a waitlist of $9 billion to get into its funds.
Goldman Sachs analysts added ResMed (RMD) to the firm’s APAC Conviction List as part of its monthly update. The firm expects “robust” ...
Improving economic conditions and a more favorable regulatory environment give Goldman Sachs catalysts to benefit from in the ...
Goldman Sachs analyst Salveen Richter initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target a Summit’s lead ...
ASX 200 futures are down 69pts (-0.84%) as of 8:30 am AEDT. In a nutshell: Nasdaq logs worst day in a month S&P 500 turns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback